Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients

References

• Kassouf W, Traboulsi SL, Kulkarni GS, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015;9:E690–E704.
   PubMed Web of Science ®Google Scholar
• Shen PL, Lin ME, Hong YK, et al. Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. World J Surg Oncol. 2018;16:197.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–653.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–442.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477.
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–2330.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66:253–262.
   PubMed Web of Science ®Google Scholar
• Wong MC, Fung FD, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8:1129.
   PubMed Web of Science ®Google Scholar
• Ourfali S, Ohannessian R, Fassi-Fehri H, et al. Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Guérin Connaught strain for bladder cancer patients. Eur Urol Focus. 2019. [Online ahead of print]. DOI:10.1016/j.euf.2019.04.002
   Google Scholar
• Perera M, Papa N, Christidis D, et al. The impact of the global bacille Calmette–Guérin shortage on treatment patterns: population-based data. BJU Int. 2018;121:169–172.
   Web of Science ®Google Scholar
• Messing EM. The BCG shortage. Bladder Cancer. 2017;3:227–228.
   Web of Science ®Google Scholar
• Rayn KN, Hale GR, Pena la Grave G, et al. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018;34:11–19.
   Web of Science ®Google Scholar
• Douglass L, Schoenberg M. The future of intravesical drug delivery for non-muscle invasive bladder cancer. Bladder Cancer. 2016;2:285–292.
   PubMed Web of Science ®Google Scholar
• Joice GA, Bivalacqua TJ, Kates M. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nat Rev Urol. 2019;16:599–612.
   Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93:597–604.
   PubMed Web of Science ®Google Scholar
• Slater SE, Patel P, Viney R, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Ann R Coll Surg Engl. 2014;96:415–419.
   PubMed Web of Science ®Google Scholar
• Soria F, Milla P, Fiorito C, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I–II study. World J Urol. 2016;34:189–195.
   PubMed Web of Science ®Google Scholar
• Colombo R, Brausi M, da Pozzo LF, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: a pilot study on marker lesion. Eur Urol. 2001;39:95–100.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Di Stasi SM, Chancellor MB, et al. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50:1183–1193.
   PubMed Web of Science ®Google Scholar
• Hendricksen K. Device-assisted intravesical therapy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8:94–100.
   Web of Science ®Google Scholar
• Moskovitz B, Meyer G, Kravtzov A, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol. 2005;16:585–589.
   PubMed Web of Science ®Google Scholar
• Longo TA, Gopalakrishna A, Tsivian M, et al. A systematic review of regional hyperthermia therapy in bladder cancer. Int J Hyperthermia. 2016;32:381–389.
   PubMed Web of Science ®Google Scholar
• Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38:1276–1296.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
   PubMed Web of Science ®Google Scholar
• Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12:871–879.
   PubMed Web of Science ®Google Scholar
• Carando R, Zazzara M, Cotrufo S, et al. Intravesical treatment with electro-mediated administration of mytomicin c as prophylaxis for intermediate and high-risk nonmuscle-invasive bladder cancer: a retrospective multicenter study. Urol Int. 2019;103:285–290.
   Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170:777–782.
   PubMed Web of Science ®Google Scholar
• Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology. 1998;51:506–509.
   PubMed Web of Science ®Google Scholar
• Riedl CR, Knoll M, Plas E, et al. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol. 1998;159:1851–1856.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107:912–918.
   PubMed Web of Science ®Google Scholar
• Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192:708–713.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69:1046–1052.
   PubMed Web of Science ®Google Scholar
• Frau JG, Palou J, Rodríguez O, et al. Failure of bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: definition and treatment options. Arch Esp Urol. 2016;69:423–433.
   Web of Science ®Google Scholar
• Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62:1088–1096.
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3(Suppl 4):S199–205.
   Google Scholar
• Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49:790–797.
   PubMed Web of Science ®Google Scholar
• Racioppi M, Di Gianfrancesco L, Ragonese M, et al. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “bCG failure” non-muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer. 2018;18:1224.
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, et al. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2014;30:171–175.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non–muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a Phase III, open-label, randomised controlled trial. Eur Urol. 2019;75:63–71.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial. Lancet Oncol. 2006;7:43–51.
   PubMed Web of Science ®Google Scholar
• Gan C, Amery S, Chatterton K, et al. Sequential bacillus Calmette-Guérin/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195:1697–1703.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes JA. Treatment of intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Eur Urol Suppl. 2007;6:P800–808.
   Web of Science ®Google Scholar
• Horvath A, Mostafid H. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. BJU Int. 2009;103:726–729.
   PubMed Web of Science ®Google Scholar